SA 57
| 中文名称 | SA 57 |
|---|---|
| 中文同义词 | 化合物 T12826;化合物 SA57 |
| 英文名称 | SA 57 |
| 英文同义词 | 4-[2-(4-Chlorophenyl)ethyl]-1-piperidinecarboxylic acid 2-(methylamino)-2-oxoethyl ester;SA 57;1-Piperidinecarboxylic acid, 4-[2-(4-chlorophenyl)ethyl]-, 2-(methylamino)-2-oxoethyl ester;SA57,SA-57 |
| CAS号 | 1346169-63-8 |
| 分子式 | C17H23ClN2O3 |
| 分子量 | 338.83 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 1346169-63-8.mol |
| 结构式 | ![]() |
SA 57 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | 二甲基亚砜:25mM;乙醇:20 mM |
| 形态 | 结晶固体 |
| 颜色 | 白色至米白色 |
IC50: 3.2 nM (Mouse FAAH) and 1.9 nM (Human FAAH); 410 nM (Mouse MAGL) and 1.4 μM (Human MAGL); 850 nM (Mouse ABHD6)
O-Aryl carbamate and N-aryl urea inhibitors have been shown to irreversibly inhibit FAAH by carbamylation of the enzyme’s serine nucleophile. SA57 exhibits clear time-dependent inhibition of FAAH and MAGL, suggesting a covalent mechanism of inactivation, presumably through carbamylation of the active site serine nucleophiles of these enzymes.
SA57 (0.01-12.5 mg/kg; intraperitoneal injection; for 2 hours; C57Bl/6 mice) treatment shows distinct dose-responsive activity against brain serine hydrolases (FAAH, MAGL and ABHD6) in vivo.
| Animal Model: | C57Bl/6 mice |
| Dosage: | 0.01 mg/kg, 0.05 mg/kg, 0.25 mg/kg, 1.25 mg/kg, 6.25 mg/kg, 12.5 mg/kg |
| Administration: | Intraperitoneal injection; for 2 hours |
| Result: | Showed distinct dose-responsive activity against brain serine hydrolases. Inhibited FAAH, MAGL and ABHD6 in vivo. |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025/12/22 | HY-103463 | SA57 | 1346169-63-8 | 1 mg | 670元 |
